16:45 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

Bridge Biotherapeutics's BBT-877 reduces lung fibrosis in mouse model of IPF

Bridge Biotherapeutics Inc. (Seongnam, South Korea) said BBT-877 reduced lung fibrosis as measured by Ashcroft scores and deposition of collagen in a mouse model of bleomycin-induced idiopathic pulmonary fibrosis (IPF). Data were presented at the...
23:30 , May 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis In vitro and mouse studies identified a hydroxamic acid-based ENPP2 inhibitor that could help treat pulmonary fibrosis. Chemical synthesis and in vitro testing in enzymatic activity assays of hydroxamic acid analogs yielded a...
20:41 , Aug 18, 2017 |  BioCentury  |  Finance

IPF call options

Surprise readouts from two programs in idiopathic pulmonary fibrosis have generated over $1.4 billion in market value, and there could still be plenty of upside ahead. After market close on Aug. 7, FibroGen Inc. (NASDAQ:FGEN) reported...
20:56 , Aug 17, 2017 |  BC Innovations  |  Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
15:44 , Aug 11, 2017 |  BC Week In Review  |  Clinical News

Galapagos' GLPG1690 improves FVC in Phase IIa for IPF

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) reported top-line data from the Phase IIa FLORA trial in 23 patients with idiopathic pulmonary fibrosis (IPF) showing that once-daily 600 mg oral GLPG1690 increased mean forced vital capacity (FVC) from...
20:40 , Aug 10, 2017 |  BC Extra  |  Clinical News

Galapagos gains on Phase IIa IPF readout

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said GLPG1690 stabilized lung function in patients with idiopathic pulmonary fibrosis in the Phase IIa FLORA trial. The company plans to "rapidly progress" the selective autotaxin (ENPP2; ATX) inhibitor into a...
20:45 , Jul 7, 2017 |  BC Week In Review  |  Company News

Merck KGaA spins out cancer newco iOnctura with partner Cancer Research UK

Merck KGaA (Xetra:MRK) said that its Merck Ventures arm created immuno-oncology newco iOnctura S.A. (Geneva, Switzerland) with an undisclosed seed investment. The newco launched with two unnamed assets spun out of Merck’s Healthcare R&D portfolio,...
05:19 , Jun 16, 2017 |  BC Week In Review  |  Company News

LegoChem grants Bridge Biotherapeutics rights to autotaxin candidate

Bridge Biotherapeutics Inc. (Seongnam, South Korea) said it received exclusive, worldwide rights to a small molecule inhibitor of autotaxin (ENPP2; ATX) from LegoChem Biosciences Inc. (KOSDAQ:141080). LegoChem will receive KrW2 billion ($1.8 million) up front...
12:56 , Mar 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary Patient sample and mouse studies suggest inhibiting LPAR1-ENPP2 signaling could help treat bronchiolitis obliterans syndrome following lung transplantation. In lung mesenchymal cells from lung transplant patients, ENPP2 levels were higher in patients with bronchiolitis...
01:59 , Dec 1, 2016 |  BC Innovations  |  Targets & Mechanisms

Not a peripheral story

By sourcing T cells directly from the pancreatic islets of Type I diabetes patients, rather than the standard method of taking blood samples, an academic team has provided an unprecedented view into the molecules that...